4.5 Article

Singapore Undiagnosed Disease Program: Genomic Analysis aids Diagnosis and Clinical Management

Journal

ARCHIVES OF DISEASE IN CHILDHOOD
Volume 106, Issue 1, Pages 31-37

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/archdischild-2020-319180

Keywords

-

Categories

Funding

  1. Singapore Ministry of Health's National Medical Research Council [NMRC/CISSP/003/2016, NMRC/CG/M003/2017, NMRC/CG/006/2013, NMRC 1056/2011, NMRC 0021/2012]
  2. SingHealth Duke-NUS Academic Medical Centre [02/FY2016/P1/03-A14]
  3. Clinical Innovation Grant from SingHealth Duke-NUS Paediatric ACP
  4. Singapore Ministry of Health's Biomedical Research Council [IAF 311019]
  5. Strategic Positioning Fund on Genetic Orphan Diseases from A*STAR, Singapore

Ask authors/readers for more resources

Using NGS technology, particularly WES or WGS, can improve diagnostic yield in patients with suspected genetic disorders in the Asian setting. Trio sequencing shows higher diagnostic yield for certain phenotypes, and positive results can lead to changes in patient treatment.
Objective Use next-generation sequencing (NGS) technology to improve our diagnostic yield in patients with suspected genetic disorders in the Asian setting. Design A diagnostic study conducted between 2014 and 2019 (and ongoing) under the Singapore Undiagnosed Disease Program. Date of last analysis was 1 July 2019. Setting Inpatient and outpatient genetics service at two large academic centres in Singapore. Patients Inclusion criteria: patients suspected of genetic disorders, based on abnormal antenatal ultrasound, multiple congenital anomalies and developmental delay. Exclusion criteria: patients with known genetic disorders, either after clinical assessment or investigations (such as karyotype or chromosomal microarray). Interventions Use of NGS technology-whole exome sequencing (WES) or whole genome sequencing (WGS). Main outcome measures (1) Diagnostic yield by sequencing type, (2) diagnostic yield by phenotypical categories, (3) reduction in time to diagnosis and (4) change in clinical outcomes and management. Results We demonstrate a 37.8% diagnostic yield for WES (n=172) and a 33.3% yield for WGS (n=24). The yield was higher when sequencing was conducted on trios (40.2%), as well as for certain phenotypes (neuromuscular, 54%, and skeletal dysplasia, 50%). In addition to aiding genetic counselling in 100% of the families, a positive result led to a change in treatment in 27% of patients. Conclusion Genomic sequencing is an effective method for diagnosing rare disease or previous 'undiagnosed' disease. The clinical utility of WES/WGS is seen in the shortened time to diagnosis and the discovery of novel variants. Additionally, reaching a diagnosis significantly impacts families and leads to alteration in management of these patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available